Cellosaurus cell line ARD-EZH2i-R (CVCL

Cellosaurus ARD-EZH2i-R (CVCL_A5RY)

Cross-references
Cell line name	ARD-EZH2i-R
Synonyms	ARD_EZH2i_R; ARD-R
Accession	CVCL_A5RY
Resource Identification Initiative	To cite this cell line use: ARD-EZH2i-R (RRID:CVCL_A5RY)
Comments	Selected for resistance to: ChEBI; CHEBI:167693; 1-isopropyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-6-(2-(4-methylpiperazin-1-yl)pyridin-4-yl)-1H-indazole-4-carboxamide (GSK343). Omics: Transcriptome analysis by RNAseq. Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371. Cell type: B-cell; CL=CL_0000236.
Sequence variations	Gene deletion; HGNC; 12637; KDM6A; Zygosity=Homozygous (PubMed=29045832). Gene fusion; HGNC; 5722; IGKJ4 + HGNC; 5732; IGKV1-16; Name(s)=IGKV1-16-IGKJ4 (from parent cell line). Gene fusion; HGNC; 5723; IGKJ5 + HGNC; 5732; IGKV1-16; Name(s)=IGKV1-16-IGKJ5 (from parent cell line).
Disease	Plasma cell myeloma (NCIt: C3242) Multiple myeloma (ORDO: Orphanet_29073)
Species of origin	Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy	Parent: CVCL_XD83 (ARD)
Sex of cell	Female
Age at sampling	Age unspecified
Category	Cancer cell line
Publications	PubMed=29045832; DOI=10.1016/j.celrep.2017.09.078; PMCID=PMC5706555 Ezponda T., Dupere-Richer D., Will C.M., Small E.C., Varghese N., Patel T., Nabet B., Popovic R., Oyer J., Bulic M., Zheng Y.-P., Huang X.-X., Shah M.Y., Maji S., Riva A., Occhionorelli M., Tonon G., Kelleher N.L., Keats J.J., Licht J.D. UTX/KDM6A loss enhances the malignant phenotype of multiple myeloma and sensitizes cells to EZH2 inhibition. Cell Rep. 21:628-640(2017)
Encyclopedic resources	Wikidata; Q107113377
Gene expression databases	GEO; GSM2774138 GEO; GSM2774141 GEO; GSM2774143 GEO; GSM2774146
Entry history
Entry creation	20-May-2021
Last entry update	10-Sep-2024
Version number	5